No association between body mass index and immunotoxicity or clinical outcomes for immune checkpoint inhibitors. Supplementary Table
收藏数据链接：
官方服务：
资源简介：
<strong>Supplementary Table 1. </strong>Development of immune-related adverse events (irAEs) and treatment response in patients with melanoma treated with immune checkpoint inhibitors at a single center, categorized by body mass index. Values are expressed as n (%), unless otherwise specified.
提供机构：
Taylor & Francis创建时间：
2022-06-13
